PepsiCo, Alphabet And 3 Stocks To Watch Heading Into Thursday - Alphabet ( NASDAQ:GOOGL ) , Bristol-Myers Squibb ( NYSE:BMY )
With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Bristol-Myers Squibb Company BMY to report quarterly earnings at $1.49 per share on revenue of $10.70 billion before the opening bell, ...
Trump's Team Blasts EU's Nearly $800 Million Fine On Apple And Meta As 'Extortion' - Could US Retaliate Against The Digital Markets Act? - Meta Platforms ( NASDAQ:META )
The European Union's first major enforcement of its sweeping Digital Markets Act has sparked political backlash in Washington - and could ignite a new front in U.S.-EU trade tensions. What Happened: On Wednesday, the European Commission fined Apple Inc.
World's largest sovereign wealth fund reports $40 billion loss in first quarter on tech downturn
Norway's sovereign wealth fund on Thursday reported a first-quarter loss of 415 billion kroner ($40 billion), citing weakness in the tech sector.
Novavax ( NVAX ) Surges 19.5%: Is This an Indication of Further Gains?
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
NB Private Equity Partners Announces Transaction in Own Shares
THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS ...
Prosecutors seek over 6 years prison for Mango Markets exploiter
US federal prosecutors have asked a district judge to sentence Avraham "Avi" Eisenberg, the crypto user convicted of the $110 million exploit of the decentralized exchange Mango Markets in 2022, to at least six and a half years behind bars.Ahead of Eisenberg's May 1 sentencing hearing, US ...
Late-breaking elafibranor primary sclerosing cholangitis ( PSC ) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
PARIS, FRANCE, 24 April 2025 Ipsen ( Euronext: IPN. ADR: IPSEY ) will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European Association for the Study of the Liver ( EASL ) congress as an oral presentation, on 10 May at ...
